# A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)

> **NCT06190093** · PHASE3 · COMPLETED · sponsor: **Outlook Therapeutics, Inc.** · enrollment: 400 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration
- Age-Related Macular Degeneration
- Wet Macular Degeneration

## Interventions

- **BIOLOGICAL:** bevacizumab
- **BIOLOGICAL:** ranibizumab

## Key facts

- **NCT ID:** NCT06190093
- **Lead sponsor:** Outlook Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-24
- **Primary completion:** 2024-11-07
- **Final completion:** 2024-12-05
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06190093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06190093, "A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06190093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*